P95 BV ('P95'), a Belgium-based global company involved in clinical and epidemiology research solutions, with a focus on vaccines and infectious diseases, announced on Tuesday that it has acquired 4Clinics, a Belgium-based Contract Research Organisation (CRO) providing Data Management, Biostatistics, Scientific Writing, Regulatory Affairs and Clinical Operations services for clinical and epidemiological studies with expertise in vaccines, immunotherapeutics and medical devices.

The 4Clinic's team and operations have been completely integrated into the P95 group effective 1 July 2024

Thomas Verstraeten, P95 CEO, commented: "I am very excited to have the 4Clinics team as part of the P95 group. 4Clinics has a long history of supporting a wide range of customers across the globe, and like us, is well known for its expertise in vaccines and infectious disease. The knowledge and experience they bring, particularly in biometrics and medical writing, will significantly strengthen our capacity and enhance our ability to provide full-scale CRO services to our customers. Establishing ourselves in France will also enable us to better serve our Francophone clientele."

4Clinics president, Fabrice Degrez stated: "We are thrilled to start this strategic partnership in a competitive market where consolidation is key. By joining forces with P95, a like-minded partner sharing our Belgian roots, we are setting a robust foundation for innovation and enhanced capabilities. This collaboration underscores our commitment to excellence and ensures continuity and improved services for our customers. Together, we are dedicated to sustaining long-term advancements in our field."